OliX Pharmaceuticals,Inc (226950.KQ)

KRW 18430.0

(-6.07%)

Long Term Debt Summary of OliX Pharmaceuticals,Inc

OliX Pharmaceuticals,Inc's latest annual long term debt in 2023 was 35.36 Billion KRW , up 76.81% from previous year.
OliX Pharmaceuticals,Inc's latest quarterly long term debt in 2024 Q1 was 42.22 Billion KRW , up 19.4% from previous quarter.
OliX Pharmaceuticals,Inc reported annual long term debt of 20 Billion KRW in 2022, down -1.6% from previous year.
OliX Pharmaceuticals,Inc reported annual long term debt of 20.32 Billion KRW in 2021, up 45.07% from previous year.
OliX Pharmaceuticals,Inc reported quarterly long term debt of 25.75 Billion KRW for 2024 Q2, down -39.01% from previous quarter.
OliX Pharmaceuticals,Inc reported quarterly long term debt of 20 Billion KRW for 2023 Q1, down 0.0% from previous quarter.

Annual Long Term Debt Chart of OliX Pharmaceuticals,Inc (2023 - 2015)

Historical Annual Long Term Debt of OliX Pharmaceuticals,Inc (2023 - 2015)

Year	Long Term Debt	Long Term Debt Growth
2023	35.36 Billion KRW	76.81%
2022	20 Billion KRW	-1.6%
2021	20.32 Billion KRW	45.07%
2020	14.01 Billion KRW	6670.75%
2019	206.93 Million KRW	0.0%
2018	- KRW	-100.0%
2017	1.4 Billion KRW	0.0%
2016	1.4 Billion KRW	0.0%
2015	- KRW	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	42.22 Billion KRW	19.4%
2024 Q2	25.75 Billion KRW	-39.01%
2023 Q1	20 Billion KRW	0.0%
2023 FY	35.36 Billion KRW	76.81%
2023 Q3	20 Billion KRW	0.0%
2023 Q2	20 Billion KRW	0.0%
2023 Q4	35.36 Billion KRW	76.81%
2022 Q2	20.38 Billion KRW	0.14%
2022 FY	20 Billion KRW	-1.6%
2022 Q4	20 Billion KRW	-2.03%
2022 Q3	20.41 Billion KRW	0.16%
2022 Q1	20.35 Billion KRW	0.13%
2021 Q4	20.32 Billion KRW	26.55%
2021 Q1	14.62 Billion KRW	2.49%
2021 Q2	15.49 Billion KRW	5.95%
2021 Q3	16.06 Billion KRW	3.67%
2021 FY	20.32 Billion KRW	45.07%
2020 Q4	14.26 Billion KRW	4590.69%
2020 FY	14.01 Billion KRW	6670.75%
2020 Q1	217.39 Million KRW	5.05%
2020 Q2	469.49 Million KRW	115.97%
2020 Q3	304.17 Million KRW	-35.21%
2019 Q4	206.93 Million KRW	307.47%
2019 FY	206.93 Million KRW	0.0%
2019 Q3	50.78 Million KRW	80.38%
2019 Q2	28.15 Million KRW	-49.53%
2019 Q1	55.78 Million KRW	0.0%
2018 Q1	- KRW	0.0%
2018 Q4	- KRW	0.0%
2018 FY	- KRW	-100.0%
2017 FY	1.4 Billion KRW	0.0%
2016 FY	1.4 Billion KRW	0.0%
2015 FY	- KRW	0.0%

Peer Long Term Debt Comparison of OliX Pharmaceuticals,Inc

Name	Long Term Debt	Long Term Debt Difference
HLB Co., Ltd.	17.93 Billion KRW	-97.185%
iNtRON Biotechnology, Inc.	258.29 Million KRW	-13590.415%
BINEX Co., Ltd.	5.57 Billion KRW	-533.908%
Bioneer Corporation	12.5 Billion KRW	-182.893%
Anterogen.Co.,Ltd.	- KRW	-Infinity%
MEDIPOST Co., Ltd.	6.99 Billion KRW	-405.533%
CrystalGenomics, Inc.	29.88 Billion USD	-18.309%
Helixmith Co., Ltd	151.68 Million KRW	-23213.316%
Chabiotech Co.,Ltd.	95.06 Billion KRW	62.804%
Medy-Tox Inc.	1.22 Billion KRW	-2784.682%
Peptron, Inc.	4.5 Billion KRW	-685.814%
Amicogen, Inc.	70.65 Billion KRW	49.951%
Genexine, Inc.	22.68 Billion KRW	-55.906%
HLB Therapeutics Co.,Ltd.	1.84 Billion KRW	-1821.63%
LegoChem Biosciences, Inc.	528.37 Million KRW	-6592.556%
ALTEOGEN Inc.	1.24 Billion KRW	-2730.614%
PharmaResearch Co., Ltd.	970.71 Million KRW	-3542.837%
SillaJen, Inc.	8.13 Billion KRW	-334.64%
JETEMA, Co., Ltd.	60 Billion KRW	41.064%
Genomictree Inc.	97.51 Million KRW	-36162.522%
MedPacto, Inc.	1.68 Billion KRW	-1996.193%
D&D Pharmatech	5.12 Billion KRW	-590.573%
EASY BIO,Inc.	30 Billion KRW	-17.872%
GI Innovation, Inc.	2.9 Billion KRW	-1117.684%